Neoadjuvant chemotherapy for stage III c-N2 NSCLC disease

概要

論文の詳細を見る
From June 1986 to June 1989, we administered neoadjuvant preoperative chemotherapy to 28 patients with stage III c-N2, NSCLC. This combination chemotherapy (CDDP 80 mg/m2 day 1, VDS 3 mg/m2 day 1, 8 MMC 8 mg/m2 day 1) resulted in a response rate of 64% regardless of histologic type. The study design was considered to be safe. Clinical and histopathological effects correlated well. The accuracy of evaluation of mediastinal lymph node metastases based on CT was not completely satisfactory. Therefore, cytological or histopathological definitive diagnosis by mediastinoscopy, etc., is necessary. Although the period of this study was short, the projected estimates of survival rate are encouraging. Although actual down-staging was achieved in only a few cases, the surgical technique was simple and there were few complications.
特定非営利活動法人日本呼吸器外科学会の論文